Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke
- PMID: 40494590
- PMCID: PMC12152461
- DOI: 10.5853/jos.2024.05113
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke
Conflict of interest statement
Dr. Jin Soo Lee reported receiving grants and personal fees from GNT Pharma outside the submitted work. Dr. Ji Sung Lee reported receiving personal fees from GNT Pharma during the conduct of the study. Dr. D. Choi reported receiving personal fees from GNT Pharma during the conduct of the study. Dr. Byoung Joo Gwag is the Chief Executive Officer and Dr. Chun San An is the Clinical Development Officer of GNT Pharma. No other disclosures were reported related to the submitted work.
Figures
References
-
- Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391–397. - PubMed
-
- Gwag BJ, Lee YA, Ko SY, Lee MJ, Im DS, Yun BS, et al. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab. 2007;27:1142–1151. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources